Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy.
Guan-Zhang LiKe-Nan ZhangZheng WangHui-Min HuZhi-Liang WangRuo-Yu HuangHao-Yu JiangYou ZhaiYue-Mei FengYuan-Hao ChangRen-Peng LiFan WuFan ZengTao JiangWei ZhangPublished in: OncoTargets and therapy (2019)
Siglec-5, -7, -9, and -16 suppressed tumor immunity in different ways. Joint usage of inhibitors may be an effective means to improve the efficacy of glioma immunotherapy.